Cover Image
市场调查报告书

全球C型肝炎市场、预测:HCV药的销售额及预测、临床试验

Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials - Global

出版商 Renub Research 商品编码 276657
出版日期 内容信息 英文 87 Pages; 18 Figures; 1 Table
商品交期: 最快1-2个工作天内
价格
Back to Top
全球C型肝炎市场、预测:HCV药的销售额及预测、临床试验 Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials - Global
出版日期: 2015年08月25日 内容信息: 英文 87 Pages; 18 Figures; 1 Table
简介

C型肝炎市场,预计从2012年的市场规模到2018年成长3倍以上。HCV(C型肝炎病毒)感染,特徵是慢性感染疾病的高罹患率,HCV相关病患的负担增加,低检验率及注射药使用的扩大相关预计发病率增加,是复杂的公共卫生问题。HCV药市场成长主要起因于未满足需求高,其需求预计由强力开发平台候补药而满足。

本报告提供全球C型肝炎市相关的总括性调查、市场分析与预测、认证药的销售额与预测、各临床实验阶段的开发平台药物分析等等,为您概述为以下内容。

第1章 摘要整理

第2章 C型肝炎药:市场、预测

第3章 C型肝炎:认证药的销售额、预测

  • Pegasys
  • Pegintron
  • Incivek
  • Victrelis

第4章 C型肝炎:契约、收购

第5章 C型肝炎:开发平台药物临床实验(阶段)Ⅲ

  • Simeprevir (TMC 435) (企业名: Janssen Pharmaceutical)
  • Faldaprevir (BI 201335) (企业名: Boerhinger Ingelheim)
  • Asunaprevir (BMS-650032) (企业名: Bristol-Myers Squibb)
  • Sofosbuvir (PSI-7977 or GS-7977) (企业名: Gilead Sciences)
  • Daclatasvir (BMS-790052) (企业名: Bristol-Myers Squibb)
  • BI-207127 (企业名: Boerhinger Ingelheim)
  • PEG-Interferon Lambda (企业名: Bristol-Myers Squibb)
  • ABT-450/r (Ritonavir) (企业名: Abbott Laboratories)
  • ABT-267 (企业名: Abbott Laboratories)
  • ABT-072/333 (企业名: Abbott Laboratories)
  • Alisporivir (企业名: Novartis)

第6章 C型肝炎:开发平台药物临床实验(阶段)Ⅱ

  • Mericitabine (RG-7128) (企业名: Roche)
  • Danoprevir/r (Ritonavir) (RG7227) (企业名: Roche)
  • GS-9256 (企业名: Gilead Sciences)
  • GS-9451 (企业名: Gilead Sciences)
  • MK-5172 (企业名: Merck)
  • Sovaprevir (ACH-1625) (企业名: Achillion)
  • IDX-320 (企业名: Idenix)
  • MK-8742 (企业名: Merck)
  • ACH-3102 (企业名: Achillion Pharmaceuticals, Inc)
  • IDX-719 (企业名: Idenix)
  • PPI-668 (企业名: Presidio Pharmaceuticals)
  • Setrobuvir (ANA-598) (企业名: Roche)
  • VX-222 (企业名: Vertex Pharmaceuticals)
  • GS-9669 (企业名: Gilead Sciences )
  • GS-9190 (Tegobuvir) (企业名: Gilead Sciences)
  • BMS-791325 (企业名: Bristol-Myers Squibb)

第7章 C型肝炎:开发平台药物的销售额预测

  • Simeprevir (TMC 435)
  • Faldaprevir (BI 201335) (Boerhinger Ingelheim)
  • Asunaprevir (BMS-650032)
  • Sofosbuvir (PSI-7977 or GS-7977)
  • Daclatasvir (BMS-790052)
  • ABT-450/r (Ritonavir)
  • ABT-072/333
  • Alisporivir
  • Mericitabine (RG-7128)
  • Danoprevir (RG7227)
  • GS-9256
  • Setrobuvir (ANA-598)
  • VX-222
  • GS-9190 (Tegobuvir)
  • BMS-791325

图表清单

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录

SUMMARY

Market for Hepatitis C drugs has grown with a phenomenal rate of more than US$ 13 Billion, in the year 2014 compared to 2013. In the last two years a couple of new drugs have been introduced in the market which has become a huge success and they have captured maximum market share of the Hepatitis C market. Gilead currently dominates the multi-billion dollar Hepatitis C market, but AbbVie has been trying to increase its market share since U.S. regulators approved the marketing of its Viekira Pak. Drug makers are already focusing on introducing new drugs in the market as several drugs are standing in the pipeline. Hepatitis C Drugs is anticipated to be a rosy market for future period.

This is 3rd edition report on Hepatitis C Drugs Industry by Renub Research. Report titled “Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials - Global” provides a comprehensive assessment of the fast-evolving, high-growth of Hepatitis sector. This 87 page report with 18 Figures and 1 Table studies the Hepatitis C Drug Market Landscape.

  • 1. Hepatitis C Drugs Market & Forecast (Chapter 2)
  • 2. Hepatitis C Approved Drugs Sales & Forecast (Chapter 3)
  • 3. Hepatitis C - Pipeline Drugs Sales & Forecast (Chapter 4)
  • 4. Hepatitis C Deals & Acquisitions (Chapter 5)
  • 5. Hepatitis C - Company Wise Clinical Trial Analysis (Chapter 6)

Hepatitis C - Approved Drugs Sales & Forecast (To 2020) (Chapter No. 3)

  • 1. Pegasys
  • 2. Pegintron
  • 3. Incivek
  • 4. Victrelis
  • 5. Olysio
  • 6. Sovaldi/Harvoni
  • 7. HCV Franchise
  • 8. Viekira Pak

Hepatitis C - Pipeline Drugs Sales Forecast (To 2020) (Chapter No. 4)

  • 1. Drug A (Merck & Co. Inc.)
  • 2. Drug B (Merck & Co. Inc.)
  • 3. Drug C (Bristol-Myers Squibb)

Hepatitis C - Company Wise Clinical Trial Analysis (Chapter No.5)

  • 1. AbbVie
  • 2. Bristol-Myers Squibb (BMS)
  • 3. Gilead Sciences
  • 4. Merck & Co. Inc.
  • 5. Tibotec/Janssen Therapeutics

DATA SOURCES

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Renub Research team of industry experts.

Primary sources include industry surveys and telephone interviews with industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.

Table of Contents

1. Executive Summary

2. Hepatitis C Drugs - Market & Forecast

3. Hepatitis C - Approved Drugs Sales & Forecast

  • 3.1. Pegasys Sales & Forecast
  • 3.2. Pegintron Sales & Forecast
  • 3.3. Incivek Sales
  • 3.4. Victrelis Sales & Forecast
  • 3.5. Olysio Sales & Forecast
  • 3.6. Sovaldi / Harvoni Sales & Forecast
  • 3.7. HCV Franchise Sales & Forecast
  • 3.8. Viekira Pak Sales & Forecast

4. Hepatitis C - Pipeline Drugs Sales Forecast

  • 4.1. Drug A of (Merck & Co. Inc.)
  • 4.2. Drug B of (Merck & Co. Inc.)
  • 4.3. Drug C of (Bristol-Myers Squibb)

5. Hepatitis C - Deals & Acquisitions

6. Hepatitis C - Company Wise Clinical Trials Analysis

  • 6.1. AbbVie - Clinical Trials
    • 6.1.1. Phase III
    • 6.1.2. Phase II
    • 6.1.3. Phase I
  • 6.2. Bristol-Myers Squibb (BMS) - Clinical Trials
    • 6.2.1. Phase III
    • 6.2.2. Phase II
  • 6.3. Gilead Sciences - Clinical Trials
    • 6.3.1. Phase II
  • 6.4. Merck & Co. Inc. - Clinical Trials
    • 6.4.1. Phase IV
    • 6.4.2. Phase III
    • 6.4.3. Phase II
    • 6.4.4. Phase I
  • 6.5. Tibotec / Janssen Therapeutics - Clinical Trials
    • 6.5.1. Phase IV
    • 6.5.2. Phase III
    • 6.5.3. Phase II
    • 6.5.4. Phase I

LIST OF FIGURES

  • Figure 2 1: Global - Hepatitis C Drug Market (Million US$), 2010 - 2014
  • Figure 2 2: Global - Forecast for Hepatitis C Drug Market (Million US$), 2015 - 2020
  • Figure 3 1: Global - Pegasys Sales (Million US$), 2005 - 2014
  • Figure 3 2: Global - Forecast for Pegasys Sales (Million US$), 2015 - 2020
  • Figure 3 3: Global - Pegintron Sales (Million US$), 2010 - 2014
  • Figure 3 4: Global - Forecast for Pegintron Sales (Million US$), 2015 - 2020
  • Figure 3 5: Global - Incivek Sales (Million US$), 2011 - 2014
  • Figure 3 6: Global - Victrelis Sales & Forecast (Million US$), 2011 - 2015
  • Figure 3 7: Global - Olysio Sales (Million US$), 2013 - 2014
  • Figure 3 8: Global - Forecast for Olysio Sales (Million US$), 2015 - 2020
  • Figure 3 9: Global - Sovaldi/Harvoni Sales (Million US$), 2013 - 2014
  • Figure 3 10: Global - Forecast for Sovaldi/Harvoni Sales (Million US$), 2015 - 2020
  • Figure 3 11: Global - HCV Franchise Sales & Forecast (Million US$), 2014 - 2020
  • Figure 3 12: Hepatitis C Drugs - Viekira Pak, Sovaldi & Harvoni Initial Prescription (Number), 2013, 2014
  • Figure 3 13: Global - Viekira Pak Sales & Forecast (Million US$), 2014 - 2020
  • Figure 4 1: Global - Forecast for Vaniprevir (MK-7009) Sales (Million US$), 2015 - 2020
  • Figure 4 2: Global - Forecast for Grazoprevir/Elbasvir (MK-5172 + MK-8742) Sales (Million US$), 2016 - 2020
  • Figure 4 3: Global - Forecast for PEG-Interferon Lambda Sales (Million US$), 2015 - 2020

LIST OF TABLES

  • Table 5 1: Hepatitis C - Deals & Acquisitions in the anti-HCV Drug Space, 2004 - 2012
Back to Top